Research results have shown that the preventive migraine drug erenumab shows long-term therapeutic effects even in patients who have failed preventive treatment.
The results of a study on the administration of erenumab in patients with episodic migraine who did not respond to preventive treatment, conducted by researchers including Uwer Reuter, Department of Neurology, Charité University of Berlin, Germany, were published in the international journal Neurology on 26 (doi.org/10.1212 /WNL.0000000000209349) .
Erenumab is a drug that blocks the calcitonin gene-related peptide receptor (CGRPR) to prevent migraines and was the first CGRP antagonist to receive approval from the US FDA in 2018.
A 3-year long-term follow-up result of erenumab showed that it was effective even in patients who had failed 2-4 preventive treatments.
The LIBERTY trial was designed to monitor the efficacy and safety of erenumab for 3 years in patients with episodic migraine (EM) and in those who had failed to respond to 2-4 prior preventative treatments.
Participants who had previously completed the 12-week double-blind clinical phase of erenumab were assigned to an open-label extension study in which they could receive 140 mg of erenumab once a month for an additional three years.
Primary outcomes included the proportion of participants achieving a 50% or greater reduction in monthly migraine days (MMD), mean change in MMD from baseline, and safety.
Of the 246 patients, 240 (97.6%) participated in the additional label expansion clinical study, and a total of 168 (70.0%) completed the clinical study.
As a result of the analysis, 79 patients (52.3%) with valid data in the entire population achieved a 50% or greater MMD reduction at week 168.
In the previous study, 35 (29.9%) participants experienced a reduction in MMD of more than 50% at week 12, and in the additional study, 26 of 35 (74.3%) responded that they experienced a reduction of more than 50%.
Of the 82/117 participants (70.1%) who did not achieve an optimal response rate at week 12 in the previous study, 17/82 (20.7%) experienced a reduction of more than 50% in the follow-up study. up.
Overall, mean (SD) change in MMD from baseline continued to improve over 3 years (4.4 days per week 168).
The most common adverse reactions were nasopharyngitis (28.8 people), influenza (7.5 people) and back pain (5.8 people).
Overall, 9.6% (3.9 per 100 person-years) and 6.7% (2.7 per 100 person-years) of participants reported treatment-related hypertension and constipation, respectively.
The researchers concluded that “Erenumab 140 mg showed sustained efficacy for 3 years in patients with episodic migraine who had failed 2 to 4 preventive treatments” and “no new safety-related adverse events were observed.”
#migraine #drug #erenumab #CGRP #effective #patients #failed #preventative #treatment
